Cargando…

Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease

While clinically significant cognitive impairment is the key feature of the symptomatic stages of the Alzheimer’s disease (AD) continuum, subtle cognitive decline is now known to occur years before a clinical diagnosis of mild cognitive impairment (MCI) or dementia due to AD is made. The primary aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Langhough Koscik, Rebecca, Hermann, Bruce P., Allison, Samantha, Clark, Lindsay R., Jonaitis, Erin M., Mueller, Kimberly D., Betthauser, Tobey J., Christian, Bradley T., Du, Lianlian, Okonkwo, Ozioma, Birdsill, Alex, Chin, Nathaniel, Gleason, Carey, Johnson, Sterling C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350058/
https://www.ncbi.nlm.nih.gov/pubmed/34381351
http://dx.doi.org/10.3389/fnagi.2021.688478
_version_ 1783735670104129536
author Langhough Koscik, Rebecca
Hermann, Bruce P.
Allison, Samantha
Clark, Lindsay R.
Jonaitis, Erin M.
Mueller, Kimberly D.
Betthauser, Tobey J.
Christian, Bradley T.
Du, Lianlian
Okonkwo, Ozioma
Birdsill, Alex
Chin, Nathaniel
Gleason, Carey
Johnson, Sterling C.
author_facet Langhough Koscik, Rebecca
Hermann, Bruce P.
Allison, Samantha
Clark, Lindsay R.
Jonaitis, Erin M.
Mueller, Kimberly D.
Betthauser, Tobey J.
Christian, Bradley T.
Du, Lianlian
Okonkwo, Ozioma
Birdsill, Alex
Chin, Nathaniel
Gleason, Carey
Johnson, Sterling C.
author_sort Langhough Koscik, Rebecca
collection PubMed
description While clinically significant cognitive impairment is the key feature of the symptomatic stages of the Alzheimer’s disease (AD) continuum, subtle cognitive decline is now known to occur years before a clinical diagnosis of mild cognitive impairment (MCI) or dementia due to AD is made. The primary aim of this study was to examine criterion validity evidence for an operational definition of “cognitively unimpaired-declining” (CU-D) in the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a longitudinal cohort study following cognition and risk factors from mid-life and on. Cognitive status was determined for each visit using a consensus review process that incorporated internal norms and published norms; a multi-disciplinary panel reviewed cases first to determine whether MCI or dementia was present, and subsequently whether CU-D was present, The CU-D group differed from CU-stable (CU-S) and MCI on concurrent measures of cognition, demonstrating concurrent validity. Participants who changed from CU-S to CU-D at the next study visit demonstrated greater declines than those who stayed CU-S. In addition, those who were CU-D were more likely to progress to MCI or dementia than those who were CU-S (predictive validity). In a subsample with positron emission tomography (PET) imaging, the CU-D group also differed from the CU-S and MCI/Dementia groups on measures of amyloid and tau burden, indicating that biomarker evidence of AD was elevated in those showing sub-clinical (CU-D) decline. Together, the results corroborate other studies showing that cognitive decline begins long before a dementia diagnosis and indicate that operational criteria can detect subclinical decline that may signal AD or other dementia risk.
format Online
Article
Text
id pubmed-8350058
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83500582021-08-10 Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease Langhough Koscik, Rebecca Hermann, Bruce P. Allison, Samantha Clark, Lindsay R. Jonaitis, Erin M. Mueller, Kimberly D. Betthauser, Tobey J. Christian, Bradley T. Du, Lianlian Okonkwo, Ozioma Birdsill, Alex Chin, Nathaniel Gleason, Carey Johnson, Sterling C. Front Aging Neurosci Neuroscience While clinically significant cognitive impairment is the key feature of the symptomatic stages of the Alzheimer’s disease (AD) continuum, subtle cognitive decline is now known to occur years before a clinical diagnosis of mild cognitive impairment (MCI) or dementia due to AD is made. The primary aim of this study was to examine criterion validity evidence for an operational definition of “cognitively unimpaired-declining” (CU-D) in the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a longitudinal cohort study following cognition and risk factors from mid-life and on. Cognitive status was determined for each visit using a consensus review process that incorporated internal norms and published norms; a multi-disciplinary panel reviewed cases first to determine whether MCI or dementia was present, and subsequently whether CU-D was present, The CU-D group differed from CU-stable (CU-S) and MCI on concurrent measures of cognition, demonstrating concurrent validity. Participants who changed from CU-S to CU-D at the next study visit demonstrated greater declines than those who stayed CU-S. In addition, those who were CU-D were more likely to progress to MCI or dementia than those who were CU-S (predictive validity). In a subsample with positron emission tomography (PET) imaging, the CU-D group also differed from the CU-S and MCI/Dementia groups on measures of amyloid and tau burden, indicating that biomarker evidence of AD was elevated in those showing sub-clinical (CU-D) decline. Together, the results corroborate other studies showing that cognitive decline begins long before a dementia diagnosis and indicate that operational criteria can detect subclinical decline that may signal AD or other dementia risk. Frontiers Media S.A. 2021-07-26 /pmc/articles/PMC8350058/ /pubmed/34381351 http://dx.doi.org/10.3389/fnagi.2021.688478 Text en Copyright © 2021 Langhough Koscik, Hermann, Allison, Clark, Jonaitis, Mueller, Betthauser, Christian, Du, Okonkwo, Birdsill, Chin, Gleason and Johnson. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Langhough Koscik, Rebecca
Hermann, Bruce P.
Allison, Samantha
Clark, Lindsay R.
Jonaitis, Erin M.
Mueller, Kimberly D.
Betthauser, Tobey J.
Christian, Bradley T.
Du, Lianlian
Okonkwo, Ozioma
Birdsill, Alex
Chin, Nathaniel
Gleason, Carey
Johnson, Sterling C.
Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease
title Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease
title_full Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease
title_fullStr Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease
title_full_unstemmed Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease
title_short Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease
title_sort validity evidence for the research category, “cognitively unimpaired – declining,” as a risk marker for mild cognitive impairment and alzheimer’s disease
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8350058/
https://www.ncbi.nlm.nih.gov/pubmed/34381351
http://dx.doi.org/10.3389/fnagi.2021.688478
work_keys_str_mv AT langhoughkoscikrebecca validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT hermannbrucep validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT allisonsamantha validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT clarklindsayr validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT jonaitiserinm validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT muellerkimberlyd validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT betthausertobeyj validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT christianbradleyt validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT dulianlian validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT okonkwoozioma validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT birdsillalex validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT chinnathaniel validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT gleasoncarey validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease
AT johnsonsterlingc validityevidencefortheresearchcategorycognitivelyunimpaireddecliningasariskmarkerformildcognitiveimpairmentandalzheimersdisease